Table 4.
Incidence of Symptoms of Wernicke Encephalopathy
| Dose Level; No. (%) of Patients* | |||
|---|---|---|---|
|
|
|||
| Symptom | Low Dose (n = 115) | High Dose (n = 26) | p Value |
| Confusion | 52 (45.2) | 18 (69.2) | 0.027 |
|
| |||
| Ataxia | 7 (6.1) | 9 (34.6) | < 0.001 |
|
| |||
| Ocular abnormalities* | 5 (4.3) | 9 (34.6) | < 0.001 |
| Nystagmus | 3 | 8 | |
| Abnormal eye movement | 0 | 1 | |
| Visual field defect | 0 | 2 | |
| Gaze palsy | 1 | 0 | |
| Ptosis | 1 | 0 | |
| Diplopia | 1 | 0 | |
|
| |||
| Patients with symptoms from triad† | |||
| No symptoms | 58 (50.4) | 4 (15.4) | 0.001 |
| 1 symptom | 50 (43.5) | 12 (46.2) | 0.80 |
| 2 symptoms | 7 (6.1) | 6 (23.1) | 0.007 |
| All symptoms | 0 | 4 (15.4) | < 0.001 |
*
Categories are not mutually exclusive.
†
Triad consists of confusion, ataxia, and ocular abnormalities.